Association with Outcomes and Response to Treatment of Trimethylamine N-Oxide in Heart Failure: Results from BIOSTAT-CHF
Toru Suzuki(Sapporo Medical University), Leong L. Ng(University of Leicester), Gerasimos Filippatos(National and Kapodistrian University of Athens), Daniel C. S. Chan(University of Leicester), Hans L. Hillege(University Medical Center Groningen), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Aeilko H. Zwinderman(Amsterdam Neuroscience), Marco Metra(Vita-Salute San Raffaele University), Y Yazaki(University of Leicester), Donald J. L. Jones(University of Leicester), Chim C. Lang(University of Dundee), Dirk J. van Veldhuisen(University Medical Center Groningen), Adriaan A. Voors(University Medical Center Groningen), Nilesh J. Samani(University of Leicester), Kenneth Dickstein, John G.F. Cleland(University of Glasgow), Stefan D. Anker(Charité - Universitätsmedizin Berlin), Piotr Ponikowski(Wroclaw Medical University)
Cited by 101
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k